The	O
endocannabinoid	B:C1172779
hydrolysis	O
inhibitor	O
SA	O
-	I:C4310529
57	I:C4310529
:	O
Intrinsic	O
antinociceptive	O
effects	O
,	O
augmented	O
morphine	O
-	O
induced	O
antinociception	O
,	O
and	O
attenuated	O
heroin	O
seeking	O
behavior	I:C0694536
in	O
mice	O
.	O

The	O
endocannabinoid	O
hydrolysis	O
inhibitor	O
SA	B:C4310529
-	I:C4310529
57	I:C4310529
:	O
Intrinsic	O
antinociceptive	O
effects	O
,	O
augmented	O
morphine	O
-	O
induced	O
antinociception	O
,	O
and	O
attenuated	O
heroin	O
seeking	O
behavior	I:C0694536
in	O
mice	O
.	O

The	O
endocannabinoid	O
hydrolysis	O
inhibitor	O
SA	O
-	I:C4310529
57	I:C4310529
:	O
Intrinsic	O
antinociceptive	B:C1866932
effects	O
,	O
augmented	O
morphine	O
-	O
induced	O
antinociception	O
,	O
and	O
attenuated	O
heroin	O
seeking	O
behavior	I:C0694536
in	O
mice	O
.	O

The	O
endocannabinoid	O
hydrolysis	O
inhibitor	O
SA	O
-	I:C4310529
57	I:C4310529
:	O
Intrinsic	O
antinociceptive	O
effects	O
,	O
augmented	O
morphine	B:C0026549
-	O
induced	O
antinociception	O
,	O
and	O
attenuated	O
heroin	O
seeking	O
behavior	I:C0694536
in	O
mice	O
.	O

The	O
endocannabinoid	O
hydrolysis	O
inhibitor	O
SA	O
-	I:C4310529
57	I:C4310529
:	O
Intrinsic	O
antinociceptive	O
effects	O
,	O
augmented	O
morphine	O
-	O
induced	O
antinociception	B:C1866932
,	O
and	O
attenuated	O
heroin	O
seeking	O
behavior	I:C0694536
in	O
mice	O
.	O

The	O
endocannabinoid	O
hydrolysis	O
inhibitor	O
SA	O
-	I:C4310529
57	I:C4310529
:	O
Intrinsic	O
antinociceptive	O
effects	O
,	O
augmented	O
morphine	O
-	O
induced	O
antinociception	O
,	O
and	O
attenuated	O
heroin	B:C0011892
seeking	O
behavior	I:C0694536
in	O
mice	O
.	O

The	O
endocannabinoid	O
hydrolysis	O
inhibitor	O
SA	O
-	I:C4310529
57	I:C4310529
:	O
Intrinsic	O
antinociceptive	O
effects	O
,	O
augmented	O
morphine	O
-	O
induced	O
antinociception	O
,	O
and	O
attenuated	O
heroin	O
seeking	B:C0694536
behavior	I:C0694536
in	O
mice	O
.	O

The	O
endocannabinoid	O
hydrolysis	O
inhibitor	O
SA	O
-	I:C4310529
57	I:C4310529
:	O
Intrinsic	O
antinociceptive	O
effects	O
,	O
augmented	O
morphine	O
-	O
induced	O
antinociception	O
,	O
and	O
attenuated	O
heroin	O
seeking	O
behavior	I:C0694536
in	O
mice	B:C0025929
.	O

Although	O
opioids	B:C0242402
are	O
highly	O
efficacious	O
analgesics	O
,	O
their	O
abuse	O
potential	I:C0013146
and	O
other	O
untoward	O
side	I:C0879626
effects	I:C0879626
diminish	O
their	O
therapeutic	O
utility	O
.	O

Although	O
opioids	O
are	O
highly	O
efficacious	O
analgesics	B:C0002771
,	O
their	O
abuse	O
potential	I:C0013146
and	O
other	O
untoward	O
side	I:C0879626
effects	I:C0879626
diminish	O
their	O
therapeutic	O
utility	O
.	O

Although	O
opioids	O
are	O
highly	O
efficacious	O
analgesics	O
,	O
their	O
abuse	B:C0013146
potential	I:C0013146
and	O
other	O
untoward	O
side	I:C0879626
effects	I:C0879626
diminish	O
their	O
therapeutic	O
utility	O
.	O

Although	O
opioids	O
are	O
highly	O
efficacious	O
analgesics	O
,	O
their	O
abuse	O
potential	I:C0013146
and	O
other	O
untoward	B:C0879626
side	I:C0879626
effects	I:C0879626
diminish	O
their	O
therapeutic	O
utility	O
.	O

The	O
addition	O
of	O
non-opioid	B:C0242937
analgesics	I:C0242937
offers	O
a	O
promising	O
strategy	O
to	O
reduce	O
required	O
antinociceptive	O
opioid	O
doses	O
that	O
concomitantly	O
reduce	O
opioid	O
-	I:C0027412
related	I:C0027412
side	I:C0027412
effects	I:C0027412
.	O

The	O
addition	O
of	O
non-opioid	O
analgesics	I:C0242937
offers	O
a	O
promising	O
strategy	O
to	O
reduce	O
required	O
antinociceptive	B:C1866932
opioid	O
doses	O
that	O
concomitantly	O
reduce	O
opioid	O
-	I:C0027412
related	I:C0027412
side	I:C0027412
effects	I:C0027412
.	O

The	O
addition	O
of	O
non-opioid	O
analgesics	I:C0242937
offers	O
a	O
promising	O
strategy	O
to	O
reduce	O
required	O
antinociceptive	O
opioid	B:C0242402
doses	O
that	O
concomitantly	O
reduce	O
opioid	O
-	I:C0027412
related	I:C0027412
side	I:C0027412
effects	I:C0027412
.	O

The	O
addition	O
of	O
non-opioid	O
analgesics	I:C0242937
offers	O
a	O
promising	O
strategy	O
to	O
reduce	O
required	O
antinociceptive	O
opioid	O
doses	O
that	O
concomitantly	O
reduce	O
opioid	B:C0027412
-	I:C0027412
related	I:C0027412
side	I:C0027412
effects	I:C0027412
.	O

Inhibitors	B:C0243077
of	O
the	O
primary	O
endocannabinoid	O
catabolic	O
enzymes	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
(	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
)	O
and	O
monoacylglycerol	O
lipase	I:C0026452
(	O
monoacylglycerol	O
lipase	I:C0026452
)	O
show	O
opioid	O
-	O
sparing	O
effects	I:C0879626
in	O
preclinical	O
models	I:C1514292
of	O
pain	O
.	O

Inhibitors	O
of	O
the	O
primary	O
endocannabinoid	B:C1172779
catabolic	O
enzymes	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
(	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
)	O
and	O
monoacylglycerol	O
lipase	I:C0026452
(	O
monoacylglycerol	O
lipase	I:C0026452
)	O
show	O
opioid	O
-	O
sparing	O
effects	I:C0879626
in	O
preclinical	O
models	I:C1514292
of	O
pain	O
.	O

Inhibitors	O
of	O
the	O
primary	O
endocannabinoid	O
catabolic	B:C1516314
enzymes	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
(	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
)	O
and	O
monoacylglycerol	O
lipase	I:C0026452
(	O
monoacylglycerol	O
lipase	I:C0026452
)	O
show	O
opioid	O
-	O
sparing	O
effects	I:C0879626
in	O
preclinical	O
models	I:C1514292
of	O
pain	O
.	O

Inhibitors	O
of	O
the	O
primary	O
endocannabinoid	O
catabolic	O
enzymes	B:C0014442
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
(	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
)	O
and	O
monoacylglycerol	O
lipase	I:C0026452
(	O
monoacylglycerol	O
lipase	I:C0026452
)	O
show	O
opioid	O
-	O
sparing	O
effects	I:C0879626
in	O
preclinical	O
models	I:C1514292
of	O
pain	O
.	O

Inhibitors	O
of	O
the	O
primary	O
endocannabinoid	O
catabolic	O
enzymes	O
fatty	B:C0531004
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
(	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
)	O
and	O
monoacylglycerol	O
lipase	I:C0026452
(	O
monoacylglycerol	O
lipase	I:C0026452
)	O
show	O
opioid	O
-	O
sparing	O
effects	I:C0879626
in	O
preclinical	O
models	I:C1514292
of	O
pain	O
.	O

Inhibitors	O
of	O
the	O
primary	O
endocannabinoid	O
catabolic	O
enzymes	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
(	O
fatty	B:C0531004
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
)	O
and	O
monoacylglycerol	O
lipase	I:C0026452
(	O
monoacylglycerol	O
lipase	I:C0026452
)	O
show	O
opioid	O
-	O
sparing	O
effects	I:C0879626
in	O
preclinical	O
models	I:C1514292
of	O
pain	O
.	O

Inhibitors	O
of	O
the	O
primary	O
endocannabinoid	O
catabolic	O
enzymes	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
(	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
)	O
and	O
monoacylglycerol	B:C0026452
lipase	I:C0026452
(	O
monoacylglycerol	O
lipase	I:C0026452
)	O
show	O
opioid	O
-	O
sparing	O
effects	I:C0879626
in	O
preclinical	O
models	I:C1514292
of	O
pain	O
.	O

Inhibitors	O
of	O
the	O
primary	O
endocannabinoid	O
catabolic	O
enzymes	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
(	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
)	O
and	O
monoacylglycerol	O
lipase	I:C0026452
(	O
monoacylglycerol	B:C0026452
lipase	I:C0026452
)	O
show	O
opioid	O
-	O
sparing	O
effects	I:C0879626
in	O
preclinical	O
models	I:C1514292
of	O
pain	O
.	O

Inhibitors	O
of	O
the	O
primary	O
endocannabinoid	O
catabolic	O
enzymes	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
(	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
)	O
and	O
monoacylglycerol	O
lipase	I:C0026452
(	O
monoacylglycerol	O
lipase	I:C0026452
)	O
show	O
opioid	B:C0242402
-	O
sparing	O
effects	I:C0879626
in	O
preclinical	O
models	I:C1514292
of	O
pain	O
.	O

Inhibitors	O
of	O
the	O
primary	O
endocannabinoid	O
catabolic	O
enzymes	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
(	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
)	O
and	O
monoacylglycerol	O
lipase	I:C0026452
(	O
monoacylglycerol	O
lipase	I:C0026452
)	O
show	O
opioid	O
-	O
sparing	B:C0879626
effects	I:C0879626
in	O
preclinical	O
models	I:C1514292
of	O
pain	O
.	O

Inhibitors	O
of	O
the	O
primary	O
endocannabinoid	O
catabolic	O
enzymes	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
(	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
)	O
and	O
monoacylglycerol	O
lipase	I:C0026452
(	O
monoacylglycerol	O
lipase	I:C0026452
)	O
show	O
opioid	O
-	O
sparing	O
effects	I:C0879626
in	O
preclinical	B:C1514292
models	I:C1514292
of	O
pain	O
.	O

Inhibitors	O
of	O
the	O
primary	O
endocannabinoid	O
catabolic	O
enzymes	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
(	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
)	O
and	O
monoacylglycerol	O
lipase	I:C0026452
(	O
monoacylglycerol	O
lipase	I:C0026452
)	O
show	O
opioid	O
-	O
sparing	O
effects	I:C0879626
in	O
preclinical	O
models	I:C1514292
of	O
pain	B:C0030193
.	O

As	O
simultaneous	O
inhibition	O
of	O
these	O
enzymes	B:C0014442
elicits	O
enhanced	O
antinociceptive	O
effects	O
compared	O
with	O
single	O
enzyme	O
inhibition	I:C1524081
,	O
the	O
present	O
study	O
tested	O
whether	O
the	O
dual	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
-	O
monoacylglycerol	O
lipase	I:C0026452
inhibitor	O
SA	O
-	I:C4310529
57	I:C4310529
[	O
4-[	O
2-(4-	I:C4310529
chlorophenyl	I:C4310529
)	I:C4310529
ethyl	I:C4310529
]	I:C4310529
-	I:C4310529
1-	I:C4310529
piperidinecarboxylic	I:C4310529
acid	I:C4310529
2	I:C4310529
-	I:C4310529
(	I:C4310529
methylamino	I:C4310529
)	I:C4310529
-	I:C4310529
2-	I:C4310529
oxoethyl	I:C4310529
ester	I:C4310529
]	O
produces	O
morphine	O
-	O
sparing	O
antinociceptive	O
effects	O
,	O
without	O
major	O
side	O
effects	I:C0879626
associated	O
with	O
either	O
drug	O
class	I:C1254351
.	O

As	O
simultaneous	O
inhibition	O
of	O
these	O
enzymes	O
elicits	O
enhanced	O
antinociceptive	B:C1866932
effects	O
compared	O
with	O
single	O
enzyme	O
inhibition	I:C1524081
,	O
the	O
present	O
study	O
tested	O
whether	O
the	O
dual	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
-	O
monoacylglycerol	O
lipase	I:C0026452
inhibitor	O
SA	O
-	I:C4310529
57	I:C4310529
[	O
4-[	O
2-(4-	I:C4310529
chlorophenyl	I:C4310529
)	I:C4310529
ethyl	I:C4310529
]	I:C4310529
-	I:C4310529
1-	I:C4310529
piperidinecarboxylic	I:C4310529
acid	I:C4310529
2	I:C4310529
-	I:C4310529
(	I:C4310529
methylamino	I:C4310529
)	I:C4310529
-	I:C4310529
2-	I:C4310529
oxoethyl	I:C4310529
ester	I:C4310529
]	O
produces	O
morphine	O
-	O
sparing	O
antinociceptive	O
effects	O
,	O
without	O
major	O
side	O
effects	I:C0879626
associated	O
with	O
either	O
drug	O
class	I:C1254351
.	O

As	O
simultaneous	O
inhibition	O
of	O
these	O
enzymes	O
elicits	O
enhanced	O
antinociceptive	O
effects	O
compared	O
with	O
single	O
enzyme	B:C1524081
inhibition	I:C1524081
,	O
the	O
present	O
study	O
tested	O
whether	O
the	O
dual	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
-	O
monoacylglycerol	O
lipase	I:C0026452
inhibitor	O
SA	O
-	I:C4310529
57	I:C4310529
[	O
4-[	O
2-(4-	I:C4310529
chlorophenyl	I:C4310529
)	I:C4310529
ethyl	I:C4310529
]	I:C4310529
-	I:C4310529
1-	I:C4310529
piperidinecarboxylic	I:C4310529
acid	I:C4310529
2	I:C4310529
-	I:C4310529
(	I:C4310529
methylamino	I:C4310529
)	I:C4310529
-	I:C4310529
2-	I:C4310529
oxoethyl	I:C4310529
ester	I:C4310529
]	O
produces	O
morphine	O
-	O
sparing	O
antinociceptive	O
effects	O
,	O
without	O
major	O
side	O
effects	I:C0879626
associated	O
with	O
either	O
drug	O
class	I:C1254351
.	O

As	O
simultaneous	O
inhibition	O
of	O
these	O
enzymes	O
elicits	O
enhanced	O
antinociceptive	O
effects	O
compared	O
with	O
single	O
enzyme	O
inhibition	I:C1524081
,	O
the	O
present	O
study	O
tested	O
whether	O
the	O
dual	O
fatty	B:C0531004
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
-	O
monoacylglycerol	O
lipase	I:C0026452
inhibitor	O
SA	O
-	I:C4310529
57	I:C4310529
[	O
4-[	O
2-(4-	I:C4310529
chlorophenyl	I:C4310529
)	I:C4310529
ethyl	I:C4310529
]	I:C4310529
-	I:C4310529
1-	I:C4310529
piperidinecarboxylic	I:C4310529
acid	I:C4310529
2	I:C4310529
-	I:C4310529
(	I:C4310529
methylamino	I:C4310529
)	I:C4310529
-	I:C4310529
2-	I:C4310529
oxoethyl	I:C4310529
ester	I:C4310529
]	O
produces	O
morphine	O
-	O
sparing	O
antinociceptive	O
effects	O
,	O
without	O
major	O
side	O
effects	I:C0879626
associated	O
with	O
either	O
drug	O
class	I:C1254351
.	O

As	O
simultaneous	O
inhibition	O
of	O
these	O
enzymes	O
elicits	O
enhanced	O
antinociceptive	O
effects	O
compared	O
with	O
single	O
enzyme	O
inhibition	I:C1524081
,	O
the	O
present	O
study	O
tested	O
whether	O
the	O
dual	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
-	O
monoacylglycerol	B:C0026452
lipase	I:C0026452
inhibitor	O
SA	O
-	I:C4310529
57	I:C4310529
[	O
4-[	O
2-(4-	I:C4310529
chlorophenyl	I:C4310529
)	I:C4310529
ethyl	I:C4310529
]	I:C4310529
-	I:C4310529
1-	I:C4310529
piperidinecarboxylic	I:C4310529
acid	I:C4310529
2	I:C4310529
-	I:C4310529
(	I:C4310529
methylamino	I:C4310529
)	I:C4310529
-	I:C4310529
2-	I:C4310529
oxoethyl	I:C4310529
ester	I:C4310529
]	O
produces	O
morphine	O
-	O
sparing	O
antinociceptive	O
effects	O
,	O
without	O
major	O
side	O
effects	I:C0879626
associated	O
with	O
either	O
drug	O
class	I:C1254351
.	O

As	O
simultaneous	O
inhibition	O
of	O
these	O
enzymes	O
elicits	O
enhanced	O
antinociceptive	O
effects	O
compared	O
with	O
single	O
enzyme	O
inhibition	I:C1524081
,	O
the	O
present	O
study	O
tested	O
whether	O
the	O
dual	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
-	O
monoacylglycerol	O
lipase	I:C0026452
inhibitor	B:C0014432
SA	O
-	I:C4310529
57	I:C4310529
[	O
4-[	O
2-(4-	I:C4310529
chlorophenyl	I:C4310529
)	I:C4310529
ethyl	I:C4310529
]	I:C4310529
-	I:C4310529
1-	I:C4310529
piperidinecarboxylic	I:C4310529
acid	I:C4310529
2	I:C4310529
-	I:C4310529
(	I:C4310529
methylamino	I:C4310529
)	I:C4310529
-	I:C4310529
2-	I:C4310529
oxoethyl	I:C4310529
ester	I:C4310529
]	O
produces	O
morphine	O
-	O
sparing	O
antinociceptive	O
effects	O
,	O
without	O
major	O
side	O
effects	I:C0879626
associated	O
with	O
either	O
drug	O
class	I:C1254351
.	O

As	O
simultaneous	O
inhibition	O
of	O
these	O
enzymes	O
elicits	O
enhanced	O
antinociceptive	O
effects	O
compared	O
with	O
single	O
enzyme	O
inhibition	I:C1524081
,	O
the	O
present	O
study	O
tested	O
whether	O
the	O
dual	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
-	O
monoacylglycerol	O
lipase	I:C0026452
inhibitor	O
SA	B:C4310529
-	I:C4310529
57	I:C4310529
[	O
4-[	O
2-(4-	I:C4310529
chlorophenyl	I:C4310529
)	I:C4310529
ethyl	I:C4310529
]	I:C4310529
-	I:C4310529
1-	I:C4310529
piperidinecarboxylic	I:C4310529
acid	I:C4310529
2	I:C4310529
-	I:C4310529
(	I:C4310529
methylamino	I:C4310529
)	I:C4310529
-	I:C4310529
2-	I:C4310529
oxoethyl	I:C4310529
ester	I:C4310529
]	O
produces	O
morphine	O
-	O
sparing	O
antinociceptive	O
effects	O
,	O
without	O
major	O
side	O
effects	I:C0879626
associated	O
with	O
either	O
drug	O
class	I:C1254351
.	O

As	O
simultaneous	O
inhibition	O
of	O
these	O
enzymes	O
elicits	O
enhanced	O
antinociceptive	O
effects	O
compared	O
with	O
single	O
enzyme	O
inhibition	I:C1524081
,	O
the	O
present	O
study	O
tested	O
whether	O
the	O
dual	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
-	O
monoacylglycerol	O
lipase	I:C0026452
inhibitor	O
SA	O
-	I:C4310529
57	I:C4310529
[	O
4-[	B:C4310529
2-(4-	I:C4310529
chlorophenyl	I:C4310529
)	I:C4310529
ethyl	I:C4310529
]	I:C4310529
-	I:C4310529
1-	I:C4310529
piperidinecarboxylic	I:C4310529
acid	I:C4310529
2	I:C4310529
-	I:C4310529
(	I:C4310529
methylamino	I:C4310529
)	I:C4310529
-	I:C4310529
2-	I:C4310529
oxoethyl	I:C4310529
ester	I:C4310529
]	O
produces	O
morphine	O
-	O
sparing	O
antinociceptive	O
effects	O
,	O
without	O
major	O
side	O
effects	I:C0879626
associated	O
with	O
either	O
drug	O
class	I:C1254351
.	O

As	O
simultaneous	O
inhibition	O
of	O
these	O
enzymes	O
elicits	O
enhanced	O
antinociceptive	O
effects	O
compared	O
with	O
single	O
enzyme	O
inhibition	I:C1524081
,	O
the	O
present	O
study	O
tested	O
whether	O
the	O
dual	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
-	O
monoacylglycerol	O
lipase	I:C0026452
inhibitor	O
SA	O
-	I:C4310529
57	I:C4310529
[	O
4-[	O
2-(4-	I:C4310529
chlorophenyl	I:C4310529
)	I:C4310529
ethyl	I:C4310529
]	I:C4310529
-	I:C4310529
1-	I:C4310529
piperidinecarboxylic	I:C4310529
acid	I:C4310529
2	I:C4310529
-	I:C4310529
(	I:C4310529
methylamino	I:C4310529
)	I:C4310529
-	I:C4310529
2-	I:C4310529
oxoethyl	I:C4310529
ester	I:C4310529
]	O
produces	O
morphine	B:C0026549
-	O
sparing	O
antinociceptive	O
effects	O
,	O
without	O
major	O
side	O
effects	I:C0879626
associated	O
with	O
either	O
drug	O
class	I:C1254351
.	O

As	O
simultaneous	O
inhibition	O
of	O
these	O
enzymes	O
elicits	O
enhanced	O
antinociceptive	O
effects	O
compared	O
with	O
single	O
enzyme	O
inhibition	I:C1524081
,	O
the	O
present	O
study	O
tested	O
whether	O
the	O
dual	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
-	O
monoacylglycerol	O
lipase	I:C0026452
inhibitor	O
SA	O
-	I:C4310529
57	I:C4310529
[	O
4-[	O
2-(4-	I:C4310529
chlorophenyl	I:C4310529
)	I:C4310529
ethyl	I:C4310529
]	I:C4310529
-	I:C4310529
1-	I:C4310529
piperidinecarboxylic	I:C4310529
acid	I:C4310529
2	I:C4310529
-	I:C4310529
(	I:C4310529
methylamino	I:C4310529
)	I:C4310529
-	I:C4310529
2-	I:C4310529
oxoethyl	I:C4310529
ester	I:C4310529
]	O
produces	O
morphine	O
-	O
sparing	O
antinociceptive	B:C1866932
effects	O
,	O
without	O
major	O
side	O
effects	I:C0879626
associated	O
with	O
either	O
drug	O
class	I:C1254351
.	O

As	O
simultaneous	O
inhibition	O
of	O
these	O
enzymes	O
elicits	O
enhanced	O
antinociceptive	O
effects	O
compared	O
with	O
single	O
enzyme	O
inhibition	I:C1524081
,	O
the	O
present	O
study	O
tested	O
whether	O
the	O
dual	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
-	O
monoacylglycerol	O
lipase	I:C0026452
inhibitor	O
SA	O
-	I:C4310529
57	I:C4310529
[	O
4-[	O
2-(4-	I:C4310529
chlorophenyl	I:C4310529
)	I:C4310529
ethyl	I:C4310529
]	I:C4310529
-	I:C4310529
1-	I:C4310529
piperidinecarboxylic	I:C4310529
acid	I:C4310529
2	I:C4310529
-	I:C4310529
(	I:C4310529
methylamino	I:C4310529
)	I:C4310529
-	I:C4310529
2-	I:C4310529
oxoethyl	I:C4310529
ester	I:C4310529
]	O
produces	O
morphine	O
-	O
sparing	O
antinociceptive	O
effects	O
,	O
without	O
major	O
side	B:C0879626
effects	I:C0879626
associated	O
with	O
either	O
drug	O
class	I:C1254351
.	O

As	O
simultaneous	O
inhibition	O
of	O
these	O
enzymes	O
elicits	O
enhanced	O
antinociceptive	O
effects	O
compared	O
with	O
single	O
enzyme	O
inhibition	I:C1524081
,	O
the	O
present	O
study	O
tested	O
whether	O
the	O
dual	O
fatty	O
acid	I:C0531004
amide	I:C0531004
hydrolase	I:C0531004
-	O
monoacylglycerol	O
lipase	I:C0026452
inhibitor	O
SA	O
-	I:C4310529
57	I:C4310529
[	O
4-[	O
2-(4-	I:C4310529
chlorophenyl	I:C4310529
)	I:C4310529
ethyl	I:C4310529
]	I:C4310529
-	I:C4310529
1-	I:C4310529
piperidinecarboxylic	I:C4310529
acid	I:C4310529
2	I:C4310529
-	I:C4310529
(	I:C4310529
methylamino	I:C4310529
)	I:C4310529
-	I:C4310529
2-	I:C4310529
oxoethyl	I:C4310529
ester	I:C4310529
]	O
produces	O
morphine	O
-	O
sparing	O
antinociceptive	O
effects	O
,	O
without	O
major	O
side	O
effects	I:C0879626
associated	O
with	O
either	O
drug	B:C1254351
class	I:C1254351
.	O

SA	B:C4310529
-	I:C4310529
57	I:C4310529
dose	O
-	O
dependently	O
reversed	O
mechanical	O
allodynia	I:C2936719
in	O
the	O
constriction	O
injury	I:C0332680
(	O
constriction	O
injury	I:C0332680
)	O
of	O
the	O
sciatic	O
nerve	I:C0036394
model	O
of	O
neuropathic	O
pain	I:C3714625
and	O
carrageenan	O
inflammatory	O
pain	I:C0234251
model	O
.	O

SA	O
-	I:C4310529
57	I:C4310529
dose	O
-	O
dependently	O
reversed	O
mechanical	B:C2936719
allodynia	I:C2936719
in	O
the	O
constriction	O
injury	I:C0332680
(	O
constriction	O
injury	I:C0332680
)	O
of	O
the	O
sciatic	O
nerve	I:C0036394
model	O
of	O
neuropathic	O
pain	I:C3714625
and	O
carrageenan	O
inflammatory	O
pain	I:C0234251
model	O
.	O

SA	O
-	I:C4310529
57	I:C4310529
dose	O
-	O
dependently	O
reversed	O
mechanical	O
allodynia	I:C2936719
in	O
the	O
constriction	B:C0332680
injury	I:C0332680
(	O
constriction	O
injury	I:C0332680
)	O
of	O
the	O
sciatic	O
nerve	I:C0036394
model	O
of	O
neuropathic	O
pain	I:C3714625
and	O
carrageenan	O
inflammatory	O
pain	I:C0234251
model	O
.	O

SA	O
-	I:C4310529
57	I:C4310529
dose	O
-	O
dependently	O
reversed	O
mechanical	O
allodynia	I:C2936719
in	O
the	O
constriction	O
injury	I:C0332680
(	O
constriction	B:C0332680
injury	I:C0332680
)	O
of	O
the	O
sciatic	O
nerve	I:C0036394
model	O
of	O
neuropathic	O
pain	I:C3714625
and	O
carrageenan	O
inflammatory	O
pain	I:C0234251
model	O
.	O

SA	O
-	I:C4310529
57	I:C4310529
dose	O
-	O
dependently	O
reversed	O
mechanical	O
allodynia	I:C2936719
in	O
the	O
constriction	O
injury	I:C0332680
(	O
constriction	O
injury	I:C0332680
)	O
of	O
the	O
sciatic	B:C0036394
nerve	I:C0036394
model	O
of	O
neuropathic	O
pain	I:C3714625
and	O
carrageenan	O
inflammatory	O
pain	I:C0234251
model	O
.	O

SA	O
-	I:C4310529
57	I:C4310529
dose	O
-	O
dependently	O
reversed	O
mechanical	O
allodynia	I:C2936719
in	O
the	O
constriction	O
injury	I:C0332680
(	O
constriction	O
injury	I:C0332680
)	O
of	O
the	O
sciatic	O
nerve	I:C0036394
model	O
of	O
neuropathic	B:C3714625
pain	I:C3714625
and	O
carrageenan	O
inflammatory	O
pain	I:C0234251
model	O
.	O

SA	O
-	I:C4310529
57	I:C4310529
dose	O
-	O
dependently	O
reversed	O
mechanical	O
allodynia	I:C2936719
in	O
the	O
constriction	O
injury	I:C0332680
(	O
constriction	O
injury	I:C0332680
)	O
of	O
the	O
sciatic	O
nerve	I:C0036394
model	O
of	O
neuropathic	O
pain	I:C3714625
and	O
carrageenan	B:C0007289
inflammatory	O
pain	I:C0234251
model	O
.	O

SA	O
-	I:C4310529
57	I:C4310529
dose	O
-	O
dependently	O
reversed	O
mechanical	O
allodynia	I:C2936719
in	O
the	O
constriction	O
injury	I:C0332680
(	O
constriction	O
injury	I:C0332680
)	O
of	O
the	O
sciatic	O
nerve	I:C0036394
model	O
of	O
neuropathic	O
pain	I:C3714625
and	O
carrageenan	O
inflammatory	B:C0234251
pain	I:C0234251
model	O
.	O

As	O
previously	O
reported	O
,	O
SA	B:C4310529
-	I:C4310529
57	I:C4310529
was	O
considerably	O
more	O
potent	O
in	O
elevating	O
anandamide	O
(	O
AEA	O
)	O
than	O
2	O
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
(	O
2	O
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
)	O
in	O
brain	O
.	O

As	O
previously	O
reported	O
,	O
SA	O
-	I:C4310529
57	I:C4310529
was	O
considerably	O
more	O
potent	O
in	O
elevating	O
anandamide	B:C0211726
(	O
AEA	O
)	O
than	O
2	O
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
(	O
2	O
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
)	O
in	O
brain	O
.	O

As	O
previously	O
reported	O
,	O
SA	O
-	I:C4310529
57	I:C4310529
was	O
considerably	O
more	O
potent	O
in	O
elevating	O
anandamide	O
(	O
AEA	B:C0211726
)	O
than	O
2	O
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
(	O
2	O
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
)	O
in	O
brain	O
.	O

As	O
previously	O
reported	O
,	O
SA	O
-	I:C4310529
57	I:C4310529
was	O
considerably	O
more	O
potent	O
in	O
elevating	O
anandamide	O
(	O
AEA	O
)	O
than	O
2	B:C0299477
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
(	O
2	O
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
)	O
in	O
brain	O
.	O

As	O
previously	O
reported	O
,	O
SA	O
-	I:C4310529
57	I:C4310529
was	O
considerably	O
more	O
potent	O
in	O
elevating	O
anandamide	O
(	O
AEA	O
)	O
than	O
2	O
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
(	O
2	B:C0299477
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
)	O
in	O
brain	O
.	O

As	O
previously	O
reported	O
,	O
SA	O
-	I:C4310529
57	I:C4310529
was	O
considerably	O
more	O
potent	O
in	O
elevating	O
anandamide	O
(	O
AEA	O
)	O
than	O
2	O
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
(	O
2	O
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
)	O
in	O
brain	B:C0006104
.	O

Its	O
anti-allodynic	B:C0243095
effects	I:C0243095
required	O
cannabinoid	O
(	I:C0378126
CB	I:C0378126
)	I:C0378126
1	I:C0378126
and	O
CB2	O
receptors	I:C0208757
;	O
however	O
,	O
only	O
CB2	O
receptors	I:C0208757
were	O
necessary	O
for	O
the	O
anti-edematous	O
effects	I:C0243095
in	O
the	O
carrageenan	O
assay	O
.	O

Its	O
anti-allodynic	O
effects	I:C0243095
required	O
cannabinoid	B:C0378126
(	I:C0378126
CB	I:C0378126
)	I:C0378126
1	I:C0378126
and	O
CB2	O
receptors	I:C0208757
;	O
however	O
,	O
only	O
CB2	O
receptors	I:C0208757
were	O
necessary	O
for	O
the	O
anti-edematous	O
effects	I:C0243095
in	O
the	O
carrageenan	O
assay	O
.	O

Its	O
anti-allodynic	O
effects	I:C0243095
required	O
cannabinoid	O
(	I:C0378126
CB	I:C0378126
)	I:C0378126
1	I:C0378126
and	O
CB2	B:C0208757
receptors	I:C0208757
;	O
however	O
,	O
only	O
CB2	O
receptors	I:C0208757
were	O
necessary	O
for	O
the	O
anti-edematous	O
effects	I:C0243095
in	O
the	O
carrageenan	O
assay	O
.	O

Its	O
anti-allodynic	O
effects	I:C0243095
required	O
cannabinoid	O
(	I:C0378126
CB	I:C0378126
)	I:C0378126
1	I:C0378126
and	O
CB2	O
receptors	I:C0208757
;	O
however	O
,	O
only	O
CB2	B:C0208757
receptors	I:C0208757
were	O
necessary	O
for	O
the	O
anti-edematous	O
effects	I:C0243095
in	O
the	O
carrageenan	O
assay	O
.	O

Its	O
anti-allodynic	O
effects	I:C0243095
required	O
cannabinoid	O
(	I:C0378126
CB	I:C0378126
)	I:C0378126
1	I:C0378126
and	O
CB2	O
receptors	I:C0208757
;	O
however	O
,	O
only	O
CB2	O
receptors	I:C0208757
were	O
necessary	O
for	O
the	O
anti-edematous	B:C0243095
effects	I:C0243095
in	O
the	O
carrageenan	O
assay	O
.	O

Its	O
anti-allodynic	O
effects	I:C0243095
required	O
cannabinoid	O
(	I:C0378126
CB	I:C0378126
)	I:C0378126
1	I:C0378126
and	O
CB2	O
receptors	I:C0208757
;	O
however	O
,	O
only	O
CB2	O
receptors	I:C0208757
were	O
necessary	O
for	O
the	O
anti-edematous	O
effects	I:C0243095
in	O
the	O
carrageenan	B:C0007289
assay	O
.	O

Its	O
anti-allodynic	O
effects	I:C0243095
required	O
cannabinoid	O
(	I:C0378126
CB	I:C0378126
)	I:C0378126
1	I:C0378126
and	O
CB2	O
receptors	I:C0208757
;	O
however	O
,	O
only	O
CB2	O
receptors	I:C0208757
were	O
necessary	O
for	O
the	O
anti-edematous	O
effects	I:C0243095
in	O
the	O
carrageenan	O
assay	B:C1510438
.	O

Although	O
high	O
doses	O
of	O
SA	B:C4310529
-	I:C4310529
57	I:C4310529
alone	O
were	O
required	O
to	O
produce	O
antinociception	O
,	O
low	O
doses	O
of	O
this	O
compound	O
,	O
which	O
elevated	O
AEA	O
and	O
did	O
not	O
affect	O
2	O
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
brain	O
levels	O
,	O
augmented	O
the	O
antinociceptive	O
effects	O
of	O
morphine	O
,	O
but	O
lacked	O
cannabimimetic	O
side	O
effects	I:C0879626
.	O

Although	O
high	O
doses	O
of	O
SA	O
-	I:C4310529
57	I:C4310529
alone	O
were	O
required	O
to	O
produce	O
antinociception	B:C1866932
,	O
low	O
doses	O
of	O
this	O
compound	O
,	O
which	O
elevated	O
AEA	O
and	O
did	O
not	O
affect	O
2	O
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
brain	O
levels	O
,	O
augmented	O
the	O
antinociceptive	O
effects	O
of	O
morphine	O
,	O
but	O
lacked	O
cannabimimetic	O
side	O
effects	I:C0879626
.	O

Although	O
high	O
doses	O
of	O
SA	O
-	I:C4310529
57	I:C4310529
alone	O
were	O
required	O
to	O
produce	O
antinociception	O
,	O
low	O
doses	O
of	O
this	O
compound	B:C4310529
,	O
which	O
elevated	O
AEA	O
and	O
did	O
not	O
affect	O
2	O
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
brain	O
levels	O
,	O
augmented	O
the	O
antinociceptive	O
effects	O
of	O
morphine	O
,	O
but	O
lacked	O
cannabimimetic	O
side	O
effects	I:C0879626
.	O

Although	O
high	O
doses	O
of	O
SA	O
-	I:C4310529
57	I:C4310529
alone	O
were	O
required	O
to	O
produce	O
antinociception	O
,	O
low	O
doses	O
of	O
this	O
compound	O
,	O
which	O
elevated	O
AEA	B:C0211726
and	O
did	O
not	O
affect	O
2	O
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
brain	O
levels	O
,	O
augmented	O
the	O
antinociceptive	O
effects	O
of	O
morphine	O
,	O
but	O
lacked	O
cannabimimetic	O
side	O
effects	I:C0879626
.	O

Although	O
high	O
doses	O
of	O
SA	O
-	I:C4310529
57	I:C4310529
alone	O
were	O
required	O
to	O
produce	O
antinociception	O
,	O
low	O
doses	O
of	O
this	O
compound	O
,	O
which	O
elevated	O
AEA	O
and	O
did	O
not	O
affect	O
2	B:C0299477
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
brain	O
levels	O
,	O
augmented	O
the	O
antinociceptive	O
effects	O
of	O
morphine	O
,	O
but	O
lacked	O
cannabimimetic	O
side	O
effects	I:C0879626
.	O

Although	O
high	O
doses	O
of	O
SA	O
-	I:C4310529
57	I:C4310529
alone	O
were	O
required	O
to	O
produce	O
antinociception	O
,	O
low	O
doses	O
of	O
this	O
compound	O
,	O
which	O
elevated	O
AEA	O
and	O
did	O
not	O
affect	O
2	O
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
brain	B:C0006104
levels	O
,	O
augmented	O
the	O
antinociceptive	O
effects	O
of	O
morphine	O
,	O
but	O
lacked	O
cannabimimetic	O
side	O
effects	I:C0879626
.	O

Although	O
high	O
doses	O
of	O
SA	O
-	I:C4310529
57	I:C4310529
alone	O
were	O
required	O
to	O
produce	O
antinociception	O
,	O
low	O
doses	O
of	O
this	O
compound	O
,	O
which	O
elevated	O
AEA	O
and	O
did	O
not	O
affect	O
2	O
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
brain	O
levels	O
,	O
augmented	O
the	O
antinociceptive	B:C1866932
effects	O
of	O
morphine	O
,	O
but	O
lacked	O
cannabimimetic	O
side	O
effects	I:C0879626
.	O

Although	O
high	O
doses	O
of	O
SA	O
-	I:C4310529
57	I:C4310529
alone	O
were	O
required	O
to	O
produce	O
antinociception	O
,	O
low	O
doses	O
of	O
this	O
compound	O
,	O
which	O
elevated	O
AEA	O
and	O
did	O
not	O
affect	O
2	O
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
brain	O
levels	O
,	O
augmented	O
the	O
antinociceptive	O
effects	O
of	O
morphine	B:C0026549
,	O
but	O
lacked	O
cannabimimetic	O
side	O
effects	I:C0879626
.	O

Although	O
high	O
doses	O
of	O
SA	O
-	I:C4310529
57	I:C4310529
alone	O
were	O
required	O
to	O
produce	O
antinociception	O
,	O
low	O
doses	O
of	O
this	O
compound	O
,	O
which	O
elevated	O
AEA	O
and	O
did	O
not	O
affect	O
2	O
-	I:C0299477
arachidonyl	I:C0299477
glycerol	I:C0299477
brain	O
levels	O
,	O
augmented	O
the	O
antinociceptive	O
effects	O
of	O
morphine	O
,	O
but	O
lacked	O
cannabimimetic	O
side	B:C0879626
effects	I:C0879626
.	O

Because	O
of	O
the	O
high	O
abuse	O
liability	O
of	O
opioids	B:C0242402
and	O
implication	O
of	O
the	O
endocannabinoid	O
system	I:C3156138
in	O
the	O
reinforcing	O
effects	O
of	O
opioids	O
,	O
the	O
final	O
experiment	O
tested	O
whether	O
SA	O
-	I:C4310529
57	I:C4310529
would	O
alter	O
heroin	O
seeking	O
behavior	I:C0694536
.	O

Because	O
of	O
the	O
high	O
abuse	O
liability	O
of	O
opioids	O
and	O
implication	O
of	O
the	O
endocannabinoid	B:C3156138
system	I:C3156138
in	O
the	O
reinforcing	O
effects	O
of	O
opioids	O
,	O
the	O
final	O
experiment	O
tested	O
whether	O
SA	O
-	I:C4310529
57	I:C4310529
would	O
alter	O
heroin	O
seeking	O
behavior	I:C0694536
.	O

Because	O
of	O
the	O
high	O
abuse	O
liability	O
of	O
opioids	O
and	O
implication	O
of	O
the	O
endocannabinoid	O
system	I:C3156138
in	O
the	O
reinforcing	O
effects	O
of	O
opioids	B:C0242402
,	O
the	O
final	O
experiment	O
tested	O
whether	O
SA	O
-	I:C4310529
57	I:C4310529
would	O
alter	O
heroin	O
seeking	O
behavior	I:C0694536
.	O

Because	O
of	O
the	O
high	O
abuse	O
liability	O
of	O
opioids	O
and	O
implication	O
of	O
the	O
endocannabinoid	O
system	I:C3156138
in	O
the	O
reinforcing	O
effects	O
of	O
opioids	O
,	O
the	O
final	O
experiment	B:C0681814
tested	O
whether	O
SA	O
-	I:C4310529
57	I:C4310529
would	O
alter	O
heroin	O
seeking	O
behavior	I:C0694536
.	O

Because	O
of	O
the	O
high	O
abuse	O
liability	O
of	O
opioids	O
and	O
implication	O
of	O
the	O
endocannabinoid	O
system	I:C3156138
in	O
the	O
reinforcing	O
effects	O
of	O
opioids	O
,	O
the	O
final	O
experiment	O
tested	O
whether	O
SA	B:C4310529
-	I:C4310529
57	I:C4310529
would	O
alter	O
heroin	O
seeking	O
behavior	I:C0694536
.	O

Because	O
of	O
the	O
high	O
abuse	O
liability	O
of	O
opioids	O
and	O
implication	O
of	O
the	O
endocannabinoid	O
system	I:C3156138
in	O
the	O
reinforcing	O
effects	O
of	O
opioids	O
,	O
the	O
final	O
experiment	O
tested	O
whether	O
SA	O
-	I:C4310529
57	I:C4310529
would	O
alter	O
heroin	B:C0011892
seeking	O
behavior	I:C0694536
.	O

Because	O
of	O
the	O
high	O
abuse	O
liability	O
of	O
opioids	O
and	O
implication	O
of	O
the	O
endocannabinoid	O
system	I:C3156138
in	O
the	O
reinforcing	O
effects	O
of	O
opioids	O
,	O
the	O
final	O
experiment	O
tested	O
whether	O
SA	O
-	I:C4310529
57	I:C4310529
would	O
alter	O
heroin	O
seeking	B:C0694536
behavior	I:C0694536
.	O

Strikingly	O
,	O
SA	B:C4310529
-	I:C4310529
57	I:C4310529
reduced	O
heroin	O
-	O
reinforced	O
nose	O
poke	O
behavior	O
and	O
the	O
progressive	O
ratio	O
break	O
point	O
for	O
heroin	O
.	O

Strikingly	O
,	O
SA	O
-	I:C4310529
57	I:C4310529
reduced	O
heroin	B:C0011892
-	O
reinforced	O
nose	O
poke	O
behavior	O
and	O
the	O
progressive	O
ratio	O
break	O
point	O
for	O
heroin	O
.	O

Strikingly	O
,	O
SA	O
-	I:C4310529
57	I:C4310529
reduced	O
heroin	O
-	O
reinforced	O
nose	O
poke	O
behavior	O
and	O
the	O
progressive	O
ratio	O
break	O
point	O
for	O
heroin	B:C0011892
.	O

In	O
conclusion	O
,	O
the	O
results	O
of	O
the	O
present	O
study	B:C0008972
suggest	O
that	O
inhibition	O
of	O
endocannabinoid	O
degradative	O
enzymes	O
represents	O
a	O
promising	O
therapeutic	O
approach	I:C0087111
to	O
decrease	O
effective	O
doses	O
of	O
opioids	O
needed	O
for	O
clinical	O
pain	O
control	I:C1304888
,	O
and	O
may	O
also	O
possess	O
therapeutic	O
potential	O
to	O
reduce	O
opioid	O
abuse	I:C0029095
.	O

In	O
conclusion	O
,	O
the	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
inhibition	B:C1524081
of	O
endocannabinoid	O
degradative	O
enzymes	O
represents	O
a	O
promising	O
therapeutic	O
approach	I:C0087111
to	O
decrease	O
effective	O
doses	O
of	O
opioids	O
needed	O
for	O
clinical	O
pain	O
control	I:C1304888
,	O
and	O
may	O
also	O
possess	O
therapeutic	O
potential	O
to	O
reduce	O
opioid	O
abuse	I:C0029095
.	O

In	O
conclusion	O
,	O
the	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
inhibition	O
of	O
endocannabinoid	B:C1172779
degradative	O
enzymes	O
represents	O
a	O
promising	O
therapeutic	O
approach	I:C0087111
to	O
decrease	O
effective	O
doses	O
of	O
opioids	O
needed	O
for	O
clinical	O
pain	O
control	I:C1304888
,	O
and	O
may	O
also	O
possess	O
therapeutic	O
potential	O
to	O
reduce	O
opioid	O
abuse	I:C0029095
.	O

In	O
conclusion	O
,	O
the	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
inhibition	O
of	O
endocannabinoid	O
degradative	B:C0699900
enzymes	O
represents	O
a	O
promising	O
therapeutic	O
approach	I:C0087111
to	O
decrease	O
effective	O
doses	O
of	O
opioids	O
needed	O
for	O
clinical	O
pain	O
control	I:C1304888
,	O
and	O
may	O
also	O
possess	O
therapeutic	O
potential	O
to	O
reduce	O
opioid	O
abuse	I:C0029095
.	O

In	O
conclusion	O
,	O
the	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
inhibition	O
of	O
endocannabinoid	O
degradative	O
enzymes	B:C0014442
represents	O
a	O
promising	O
therapeutic	O
approach	I:C0087111
to	O
decrease	O
effective	O
doses	O
of	O
opioids	O
needed	O
for	O
clinical	O
pain	O
control	I:C1304888
,	O
and	O
may	O
also	O
possess	O
therapeutic	O
potential	O
to	O
reduce	O
opioid	O
abuse	I:C0029095
.	O

In	O
conclusion	O
,	O
the	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
inhibition	O
of	O
endocannabinoid	O
degradative	O
enzymes	O
represents	O
a	O
promising	O
therapeutic	B:C0087111
approach	I:C0087111
to	O
decrease	O
effective	O
doses	O
of	O
opioids	O
needed	O
for	O
clinical	O
pain	O
control	I:C1304888
,	O
and	O
may	O
also	O
possess	O
therapeutic	O
potential	O
to	O
reduce	O
opioid	O
abuse	I:C0029095
.	O

In	O
conclusion	O
,	O
the	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
inhibition	O
of	O
endocannabinoid	O
degradative	O
enzymes	O
represents	O
a	O
promising	O
therapeutic	O
approach	I:C0087111
to	O
decrease	O
effective	O
doses	O
of	O
opioids	B:C0242402
needed	O
for	O
clinical	O
pain	O
control	I:C1304888
,	O
and	O
may	O
also	O
possess	O
therapeutic	O
potential	O
to	O
reduce	O
opioid	O
abuse	I:C0029095
.	O

In	O
conclusion	O
,	O
the	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
inhibition	O
of	O
endocannabinoid	O
degradative	O
enzymes	O
represents	O
a	O
promising	O
therapeutic	O
approach	I:C0087111
to	O
decrease	O
effective	O
doses	O
of	O
opioids	O
needed	O
for	O
clinical	O
pain	B:C1304888
control	I:C1304888
,	O
and	O
may	O
also	O
possess	O
therapeutic	O
potential	O
to	O
reduce	O
opioid	O
abuse	I:C0029095
.	O

In	O
conclusion	O
,	O
the	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
inhibition	O
of	O
endocannabinoid	O
degradative	O
enzymes	O
represents	O
a	O
promising	O
therapeutic	O
approach	I:C0087111
to	O
decrease	O
effective	O
doses	O
of	O
opioids	O
needed	O
for	O
clinical	O
pain	O
control	I:C1304888
,	O
and	O
may	O
also	O
possess	O
therapeutic	O
potential	O
to	O
reduce	O
opioid	B:C0029095
abuse	I:C0029095
.	O

